Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML).

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Aug 2016

Padron Eric, Dezern Amy, Andrade-Campos Marcio, Vaddi Kris, Scherle Peggy, Zhang Qing, Ma Yan, Balasis Maria E, Tinsley Sara, Ramadan Hanadi, Zimmerman Cassandra, Steensma David P, Roboz Gail J, Lancet Jeffrey E, List Alan F, Sekeres Mikkael A, Komrokji Rami S

Abstract excerpt

PURPOSE: To conduct a phase I clinical trial exploring the safety and efficacy of ruxolitinib, a JAK1/2 inhibitor, for chronic myelomonocytic leukemia (CMML). EXPERIMENTAL DESIGN: Patients with CMML-1 were included without regard to previous therapy. Key exclusion criteria included an absolute neutrophil count (ANC) <0.25 × 10(3) cells/dL and a platelet count <35 × 10(3) cells/dL. Four cohorts were enrolled using...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytokines
Share to Granulocyte-Macrophage Colony-Stimulating Factor

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Inflammation Mediators

Share to Leukemia, Myelomonocytic, Chronic

Share to Nitriles

Share to Pyrazoles

Share to Pyrimidines

Share to STAT5 Transcription Factor

Source

Open in PubMed Open full text

Identifiers

PMID: 26858309
DOI: 10.1158/1078-0432.CCR-15-2781
PMCID: PMC5278764

Genes

JAK1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML).PMID 26858309Read ↗

Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia.Semantic proximity Read ↗

Contemporary Risk Stratification and Treatment of Chronic Myelomonocytic Leukemia.Semantic proximity Read ↗

A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia.Semantic proximity Read ↗

Emerging drugs for the treatment of chronic myelomonocytic leukemia.Semantic proximity Read ↗

Clinical efficacy and safety of ruxolitinib in the management of myelofibrosis: A single institution experience in Taiwan.Semantic proximity Read ↗

Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study.Semantic proximity Read ↗

Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.Semantic proximity Read ↗

Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms.Semantic proximity Read ↗

Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: The RUX-MF Real-World Study.Semantic proximity Read ↗

Disease-modifying activity of ruxolitinib in a patient with JAK2-negative CMML-2.Semantic proximity Read ↗

Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial.Semantic proximity Read ↗

Efficacy of ruxolitinib for myelofibrosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.